When you buy generic medicines from India, one question naturally arises: How do I know they are safe and effective? The answer lies with India’s central drug regulatory authority — the Central Drugs Standard Control Organization (CDSCO). This guide explains how CDSCO regulates, approves, and monitors the quality of generic medicines manufactured in India, so you can make informed decisions with confidence.
🇮🇳 What Is CDSCO and Why Does It Matter for Generic Drugs?
CDSCO is the national regulatory authority (NRA) of India, operating under the Ministry of Health and Family Welfare. It functions as the Indian equivalent of the U.S. FDA or the European EMA. Headquartered in New Delhi, CDSCO oversees the approval, licensing, and quality monitoring of all pharmaceutical products manufactured, imported, and sold in India.
As reported by the Press Information Bureau (PIB, March 2026), CDSCO processes over 60,000 drug approval applications annually, making it one of the busiest drug regulatory bodies in the world. Its Drug Controller General of India (DCGI), Dr. Rajeev Singh Raghuvanshi, was reappointed in March 2026 for a second term, signaling policy continuity in the agency’s ongoing regulatory modernization efforts.
📋 Step 1: Product Approval Process for Generic Medicines
Before any generic medicine can be manufactured or sold in India, it must receive marketing authorization from CDSCO. The process involves several critical checks:
- Bioequivalence Study Review — The manufacturer must demonstrate that their generic version delivers the same active ingredient at the same concentration and absorption rate as the reference branded drug. This is done through bioequivalence (BE) studies conducted at CDSCO-approved clinical trial sites.
- Manufacturing Site Inspection — CDSCO or state drug authorities inspect the manufacturing facility to verify compliance with Schedule M of the Drugs and Cosmetics Act, which governs Good Manufacturing Practices (GMP) in India.
- Drug Master File (DMF) Review — Manufacturers must submit a DMF containing detailed information about the drug’s composition, manufacturing process, stability data, and quality control methods.
- Label and Package Insert Approval — All product labelling is reviewed to ensure it matches the approved innovator product and contains accurate information about dosage, contraindications, and side effects.
In 2026, CDSCO introduced significant reforms under the New Drugs and Clinical Trial (NDCT) Amendment Rules, reducing the statutory processing timeline for test licence applications from 90 days to 45 days, as reported by The New Indian Express (January 2026). This fast-track mechanism aims to accelerate the availability of affordable generic medicines without compromising quality.
🔬 Step 2: Good Manufacturing Practices (GMP) and Schedule M Compliance
India’s pharmaceutical manufacturing standards are governed by Schedule M of the Drugs and Cosmetics Rules, 1945. In late 2024, the Indian government notified revised Schedule M requirements aligned with WHO-GMP standards, bringing Indian manufacturing regulations in line with international benchmarks.
In November 2025, DCGI Dr. Raghuvanshi issued directives instructing all state drug regulators to strictly enforce these revised GMP standards, as reported by Drishti IAS (November 2025, citing The Indian Express). The directive targeted stricter compliance in areas including:
- Premises and equipment validation — ensuring all manufacturing equipment meets updated qualification standards
- Quality control laboratory operations — mandating separate QC labs with trained personnel at each manufacturing site
- Documentation and batch record keeping — requiring complete traceability from raw material to finished product
- Stability testing programs — ongoing monitoring of drug stability under various storage conditions
Furthermore, in February 2026, CDSCO announced a major regulatory overhaul to outsource GMP audits and build a cadre of 1,500 expert scientific personnel, as reported by IndiaMedToday (February 2026). This two-pronged approach aims to increase the frequency and thoroughness of manufacturing inspections without overburdening the existing regulatory workforce.
🌍 Step 3: WHO-GMP Certification and International Standards
For Indian generic manufacturers who export medicines globally, WHO-GMP certification is often a prerequisite. CDSCO issues WHO-GMP certificates to manufacturers whose facilities meet the quality standards set by the World Health Organization.
This certification is critical because:
- It demonstrates that the manufacturing facility operates to internationally accepted quality standards
- It is recognized by regulatory authorities in over 150 countries, including WHO-prequalified drug programs
- It serves as a foundational requirement for exporting to regulated markets including the EU, Australia, and parts of Southeast Asia
- It is increasingly required by international procurement agencies such as UNICEF, UNITAID, and the Global Fund
In July 2025, CDSCO extended the deadline for pharmaceutical units to file Certificate of Pharmaceutical Product (COPP) applications online via the ONDLS portal, as reported by Business Standard (July 2025). The COPP is the document that certifies a product is manufactured to GMP standards and is a prerequisite for export registration in many countries.
⚡ Recent 2026 Reforms: CDSCO Modernization in Action
2026 has been a landmark year for CDSCO regulatory modernization. Key reforms include:
- Prior Intimation System (January 2026) — CDSCO adopted a prior intimation system for clinical trial applications, replacing the previous approval-based model. As reported by RAPS.org (May 2026), this is designed to significantly accelerate study startup timelines for clinical trials conducted in India.
- NDCT Amendment Rules (January 2026) — Halved processing timelines for test licences from 90 to 45 days, as reported by The New Indian Express (January 2026).
- Fast-Track Foreign Drug Import Approvals (April 2026) — CDSCO moved to streamline Form 40 applications for foreign drug imports, cutting procedural delays and enabling direct electronic submission, as reported by Business Standard (April 2026).
- GMP Audit Outsourcing (February 2026) — A two-pronged overhaul to outsource inspections and recruit 1,500+ scientific personnel, as reported by IndiaMedToday (February 2026).
✅ How to Verify the Quality of Indian Generic Medicines Yourself
While CDSCO provides robust regulatory oversight, buyers can take additional steps to verify quality:
- Check for CDSCO registration number — Every approved generic medicine has a CDSCO-issued registration or manufacturing licence number printed on its packaging
- Look for WHO-GMP certification — Reputable manufacturers prominently display their WHO-GMP certificate and expiry date
- Use verified distributors — For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory
- Check batch testing records — Many quality manufacturers provide Certificate of Analysis (CoA) for each batch upon request
- Verify facility approvals — Cross-reference the manufacturer’s name against CDSCO’s publicly available list of licensed manufacturing facilities
India’s generic pharmaceutical industry is one of the most tightly regulated in the developing world, and CDSCO’s recent reforms — including the 2026 NDCT amendments, GMP audit overhaul, and import approval streamlining — demonstrate a strong commitment to quality and international standards. When you purchase generic medicines from a CDSCO-approved manufacturer with WHO-GMP certification, you are buying products that meet rigorous quality standards validated by both national and international regulators.
For more information, contact IMSDA at contact@indiamedicine.org.